Stratos Wealth Partners LTD. Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Stratos Wealth Partners LTD. cut its position in Pfizer Inc. (NYSE:PFE) by 3.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 281,526 shares of the biopharmaceutical company’s stock after selling 8,844 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Pfizer were worth $7,469,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after buying an additional 12,864,343 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Pfizer during the third quarter worth about $146,481,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock worth $211,737,000 after purchasing an additional 4,546,809 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in Pfizer by 226.7% in the third quarter. Fisher Asset Management LLC now owns 6,209,907 shares of the biopharmaceutical company’s stock valued at $179,715,000 after purchasing an additional 4,309,076 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $26.46 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm’s 50-day moving average price is $26.27 and its two-hundred day moving average price is $27.79. The stock has a market capitalization of $149.94 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.50%. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 232.44%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.